Description

This EASL Studio discusses important issues related to the opportunities and challenges of liver transplantation in acute-on-chronic liver failure (ACLF).

• Does urgent liver transplantation improve the survival of patients with ACLF-3 and where are the limits?
• Are the current allocation systems adequate and how to implement ACLF criteria for prioritisation?
• The distinct lack of equity of access of ACLF-3 patients to liver transplantation: Where are the barriers?
• What data will the CHANCE study deliver to address some of the unanswered questions?

Faculty

• Prof. Rajiv Jalan (Moderator)
• Dr Thierry Artzner (Faculty)
• Prof. Luca Belli (Faculty)
• Prof. Marina Berenguer (Faculty)

Patient perspective

• Dr Amit Verma (United Kingdom)
• Dr Devangi Verma (United Kingdom)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

This episode of EASL Studio discusses the latest data in the treatment of NAFLD presented at the EASL NAFLD Summit 2022.

Faculty

• Prof. Amalia Gastaldelli (Faculty)
• Prof. Frank Tacke (Faculty)
• Prof. Emmanuel Tsochatzis (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

People suffering from alcohol-related liver (ALD) disorders are subject to several forms of stigma. If not addressed, stigma may lead towards unfavourable health outcomes. This JHEP Live – based on a recent review – discusses:

• What forms of stigma do people suffering from ALD face?
• How does stigma affect them?
• What can be done about it?

ℹ️ Read this article for more information: G. Schomerus et al. The stigma of alcohol-related liver disease and its impact on healthcare Journal of Hepatology 2022 vol. 77 : 516–524

Faculty

• Prof. Patrizia Burra (Moderator)
• Prof. Georg Schomerus (Moderator)
• Dr Patrizia Carrieri (Faculty)
• Prof. Philippe Mathurin (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

In honour of World Hospice and Palliative Care Day (8 October), this EASL Studio episode examines:

• When is the best time to think about end-of-life care in liver disease?
• What does it mean for the liver care team?
• When and how should patients be referred to specialised palliative care?

Faculty

• Dr Patrizia Künzler-Heule (Moderator)
• Prof. Philip Larkin (Faculty)
• Dr Philip Berry (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

In recent years, the role of the gut microbiome in the development and severity of various diseases has come to light. In this episode, the experts examines:

• The role of microbiome in obesity.
• The role of microbiome in the transition from NAFLD to NASH.
• Practical solutions in microbiome medications.

Faculty

• Prof. Oren Shibolet (Moderator)
• Dr Aleksandra Kolodziejczyk (Faculty)
• Prof. Eran Elinav (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Building upon a series of discussions hosted in 2020 and 2021, The Wilton Park Dialogues (17-19 October) unites thought leaders and experts from around the world to assess the current fatty liver disease landscape and inform the development of a global research and action roadmap.

This episode of EASL Studio discusses:

• Provide an overview of the current situation.
• Give insight into changes needed to halt this growing problem.
• Review the recently held Wilton Park Dialogues.

Faculty

• Prof. Aleksander Krag (Moderator)
• Dr Marco Arrese (Faculty, ALEH representative)
• Prof. Jeffrey Lazarus (Faculty)
• Prof. Maru Rinella (Faculty, AASLD representative)
• Prof. Vincent Wong (Faculty, APASL representative)
• Prof. Zobair Younossi (Faculty)

This EASL Studio has been sponsored by Apollo Endo Surgery, Boehringer Ingelheim, BMS, MSD and Takeda. The sponsors have had no editorial control over the content featured.

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Watch this EASL Studio to find out:

• Which policies for prioritisation exist within a deceased donor liver allocation system?
• What is the impact of novel cancer therapies on the selection of patients with prior cancer?

Faculty

• Prof. Sherrie Bhoori (Moderator)
• Prof. Pål-Dag Line (Faculty)
• Prof. Vincenzo Mazzaferro (Faculty)
• Prof. Gonzalo Sapisochin (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

In this JHEP Live the faculty discuss the use of antisense oligonucleotides and siRNAs in the treatment of chronic hepatitis B infections.

Faculty

• Prof. Joerg Petersen (Moderator)
• Prof. Maria Buti (Faculty)
• Prof. Man-Fung Yuen (Faculty)

Articles of interest

• Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB
• N-acetyl galactosamine-conjugated antisense oligonucleotide (GSK3389404) in chronic hepatitis B patients on stable nucleos(t)ide therapy: Phase 2a, randomised, double-blind, controlled study

Related episodes

• Treatment of HBV-HDV coinfection in the era of entry inhibition
• JHEP Live: Stop Nuc in HBeAg negative patients
• Midday Talks: HBV and HDV drug development – Where do we stand and where are we going?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

This EASL Studio episode focuses on the pathogenesis and treatment options of the cholestatic pruritus.

Faculty

• Prof. Verena Keitel (Moderator)
• Prof. Andreas Kremer (Faculty)
• Dr Binita Kamath (Faculty)
• Prof. Ronald Oude Elferink (Faculty)

Related episodes

• New treatment options for hereditary cholestasis syndromes: A game-changer?
• Primary biliary cholangitis: A look at the future therapy landscape for patients

This EASL Studio has been sponsored by GSK and Mirum Pharmaceuticals. The sponsors have had no editorial control over the content featured.

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Currently, the only established therapeutic option for end-stage liver disease is orthotopic liver transplantation. However, the paucity of donor organs limits this option to only a few patients. From liver stem cells to advanced tissue bioengineering, this episode of EASL Studio discusses regenerative hepatology techniques as an alternative treatment for patients.

Faculty

• Prof. Pedro Baptista (Moderator)
• Prof. Tobias Cantz (Faculty)
• Prof. Karen Piper Hanley (Faculty)
• Prof. Frederic Lemaigre (Faculty)

Related episode:

• YI Choice: Propelling liver cell biology into the third dimension

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

Traditionally, journal impact factor has been the way to measure the impact of ones scientific articles. However, social media platforms are increasingly being used for the dissemination of publications. Join the faculty as they debate novel metrics to measure the impact of articles.

Faculty

• Prof. Jesus Banales (Moderator)
• Dr Atoosa Rabiee (Faculty)
• Dr Elliot Tapper (Faculty)
• Dr Juan Turnes (Faculty)

Related episode

• New era for science dissemination: The role of social media

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

As we near the end of 2022, this EASL Studio reflects upon:

• Which topics were most published about
• Which fields will we focus on in 2023
• What will the future of hepatology look like?

Faculty

• Prof. Paolo Angeli (Moderator)
• Prof. Jessica Zucman-Rossi (Moderator)
• Prof. Thomas Berg (Faculty)
• Prof. Aleksander Krag (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.